AIMS: Ectopic activation of tissue-specific genes accompanies malignant transformation in many cancers. Prolactin (PRL) aberrant activation in lung cancer was investigated here to highlight its value as a biomarker. RESULTS: PRL is ectopically activated in a subset of very aggressive lung tumors, associated with a rapid fatal outcome, in our cohort of 293 lung tumor patients and in an external independent series of patients. Surprisingly PRL receptor expression was not detected in the vast majority of PRL-expressing lung tumors. Additionally, the analysis of the PRL transcripts in lung tumors and cell lines revealed systematic truncations of their 5' regions, including the signal peptide-encoding portions. PRL expression was found to sustain cancer-specific gene expression circuits encompassing genes that are normally responsive to hypoxia. Interestingly, this analysis also indicated that histone deacetylase (HDAC) inhibitors could counteract the PRL-associated transcriptional activity. INNOVATION AND CONCLUSION: Altogether, this work not only unravels a yet unknown oncogenic mechanism but also indicates that the specific category of PRL-expressing aggressive lung cancers could be particularly responsive to an HDAC inhibitor-based treatment.
AIMS: Ectopic activation of tissue-specific genes accompanies malignant transformation in many cancers. Prolactin (PRL) aberrant activation in lung cancer was investigated here to highlight its value as a biomarker. RESULTS:PRL is ectopically activated in a subset of very aggressive lung tumors, associated with a rapid fatal outcome, in our cohort of 293 lung tumorpatients and in an external independent series of patients. Surprisingly PRL receptor expression was not detected in the vast majority of PRL-expressing lung tumors. Additionally, the analysis of the PRL transcripts in lung tumors and cell lines revealed systematic truncations of their 5' regions, including the signal peptide-encoding portions. PRL expression was found to sustain cancer-specific gene expression circuits encompassing genes that are normally responsive to hypoxia. Interestingly, this analysis also indicated that histone deacetylase (HDAC) inhibitors could counteract the PRL-associated transcriptional activity. INNOVATION AND CONCLUSION: Altogether, this work not only unravels a yet unknown oncogenic mechanism but also indicates that the specific category of PRL-expressing aggressive lung cancers could be particularly responsive to an HDAC inhibitor-based treatment.
Authors: Stephen A Bustin; Vladimir Benes; Jeremy A Garson; Jan Hellemans; Jim Huggett; Mikael Kubista; Reinhold Mueller; Tania Nolan; Michael W Pfaffl; Gregory L Shipley; Jo Vandesompele; Carl T Wittwer Journal: Clin Chem Date: 2009-02-26 Impact factor: 8.327
Authors: Emilie Montellier; Fayçal Boussouar; Sophie Rousseaux; Kai Zhang; Thierry Buchou; François Fenaille; Hitoshi Shiota; Alexandra Debernardi; Patrick Héry; Sandrine Curtet; Mahya Jamshidikia; Sophie Barral; Hélène Holota; Aurélie Bergon; Fabrice Lopez; Philippe Guardiola; Karin Pernet; Jean Imbert; Carlo Petosa; Minjia Tan; Yingming Zhao; Matthieu Gérard; Saadi Khochbin Journal: Genes Dev Date: 2013-07-24 Impact factor: 11.361
Authors: Sophie Rousseaux; Alexandra Debernardi; Baptiste Jacquiau; Anne-Laure Vitte; Aurélien Vesin; Hélène Nagy-Mignotte; Denis Moro-Sibilot; Pierre-Yves Brichon; Sylvie Lantuejoul; Pierre Hainaut; Julien Laffaire; Aurélien de Reyniès; David G Beer; Jean-François Timsit; Christian Brambilla; Elisabeth Brambilla; Saadi Khochbin Journal: Sci Transl Med Date: 2013-05-22 Impact factor: 17.956
Authors: Anouk Emadali; Sophie Rousseaux; Juliana Bruder-Costa; Claire Rome; Samuel Duley; Sieme Hamaidia; Patricia Betton; Alexandra Debernardi; Dominique Leroux; Benoit Bernay; Sylvie Kieffer-Jaquinod; Florence Combes; Elena Ferri; Charles E McKenna; Carlo Petosa; Christophe Bruley; Jérôme Garin; Myriam Ferro; Rémy Gressin; Mary B Callanan; Saadi Khochbin Journal: EMBO Mol Med Date: 2013-07-04 Impact factor: 12.137
Authors: José Manuel Cameselle-Teijeiro; José Antonio Mato Mato; Ovidio Fernández Calvo; Jesús García Mata Journal: Mol Diagn Ther Date: 2018-04 Impact factor: 4.074
Authors: Jin Wang; Jian-Qing Mi; Alexandra Debernardi; Anne-Laure Vitte; Anouk Emadali; Julia A Meyer; Konstantina Charmpi; Bernard Ycart; Mary B Callanan; William L Carroll; Saadi Khochbin; Sophie Rousseaux Journal: Oncotarget Date: 2015-06-30